Psoriatic Pruritus Drug

About AntalGenics

AntalGenics is a private, preclinical-stage biotech founded in 2015 and based in Elche, Spain, with a focus on neurobiology-driven therapies for pain, pruritus, and dermatological conditions. The company has secured substantial non-dilutive grant funding from Spanish and EU sources and completed an investment round with Capital Cell. Its pipeline includes programs for psoriatic pruritus and arthritic pain, alongside a portfolio of licensed cosmeceutical ingredients, positioning it with a hybrid model of therapeutic development and service-based R&D collaborations.

Therapeutic Areas